Publikationen 2011

Ackermann JA, Radtke D, Maurberger A, Winkler TH, Nitschke L: (2011) Grb2 regulates B-cell maturation, B-cell memory responses and inhibits B-cell Ca2+ signalling. EMBO J. 2011;30(8): 1621-33
Singer K, Kastenberger M, Gottfried E, Hammerschmied CG, Buttner M, Aigner M, Seliger B, Walter B, Schlösser H, Hartmann A, Andreesen R, Mackensen A, Kreutz M: (2011) Warburg phenotype in renal cell carcinoma: High expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor. Int J Cancer. 2011;128(9): 2085-95
Hübel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rösler W, Wehler D, Zander AR, Albert MH, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kröger N: (2011) Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant. 2011;46(8): 1045-52
Singer K, Gottfried E, Kreutz M, Mackensen A: (2011) Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother. 2011;60(3): 425-31
Voelkl S, Gary R, Mackensen A: (2011) Characterization of the immunoregulatory function of human TCR-??(+) CD4(-) CD8(-) double-negative T cells. Eur J Immunol. 2011;41(3): 739-48
Schubert I, Kellner C, Stein C, Kügler M, Schwenkert M, Saul D, Mentz K, Singer H, Stockmeyer B, Hillen W, Mackensen A, Fey GH: (2011) A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs. 2011;3(1): 21-30
Mueller SM, Spriewald BM, Bergmann S, Eismann K, Leykauf M, Korn K, Walter H, Schmidt B, Arnold ML, Harrer EG, Kaiser R, Schweitzer F, Braun P, Reuter S, Jaeger H, Wolf E, Brockmeyer NH, Jansen K, Michalik C, Harrer T, German Competence Network for HIV/AIDS: (2011) Influence of major HIV-1 protease inhibitor resistance mutations on CTL recognition. J Acquir Immune Defic Syndr. 2011;56(2): 109-17
Zwerina J, Bach C, Martorana D, Jatzwauk M, Hegasy G, Moosig F, Bremer J, Wieczorek S, Moschen A, Tilg H, Neumann T, Spriewald BM, Schett G, Vaglio A: (2011) Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford). 2011;50(10): 1823-7
Huber BC, Brunner S, Segeth A, Nathan P, Fischer R, Zaruba MM, Vallaster M, Theiss HD, David R, Gerbitz A, Franz WM: (2011) Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4+ stem cells into the ischaemic heart. Cardiovasc Res. 2011;90(3): 529-37
Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang GB, Kobbe G, Gramatzki M, Lawitschka A, Mohty M, Pavletic SZ, Greinix H, Holler E: (2011) Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2011;17(1): 1-17
Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hänel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saußele S: (2011) Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-? in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011;29(12): 1634-42
Zaiss MM, Kurowska-Stolarska M, Böhm C, Gary R, Scholtysek C, Stolarski B, Reilly J, Kerr S, Millar NL, Kamradt T, McInnes IB, Fallon PG, David JP, Liew FY, Schett G: (2011) IL-33 Shifts the Balance from Osteoclast to Alternatively Activated Macrophage Differentiation and Protects from TNF-{alpha}-Mediated Bone Loss. J Immunol. 2011;186(11): 6097-105
Kellner C, Bruenke J, Horner H, Schubert J, Schwenkert M, Mentz K, Barbin K, Stein C, Peipp M, Stockmeyer B, Fey GH: (2011) Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. Cancer Lett. 2011;303(2): 128-39
Hullard-Pulstinger A, Holler E, Hahn J, Andreesen R, Krause SW: (2011) Prophylactic application of nebulized liposomal amphotericin B in hematologic patients with neutropenia. Onkologie. 2011;34(5): 254-8
Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S: (2011) Tumor Cell Programmed Death Ligand 1-Mediated T Cell Suppression Is Overcome by Coexpression of CD80. J Immunol. 2011;186(12): 6822-9
Heindl LM, Hofmann-Rummelt C, Adler W, Bosch JJ, Holbach LM, Naumann GO, Kruse FE, Cursiefen C: (2011) Tumor-associated lymphangiogenesis in the development of conjunctival melanoma. Invest Ophthalmol Vis Sci. 2011;52(10): 7074-83
Heindl LM, Hofmann-Rummelt C, Adler W, Bosch JJ, Holbach LM, Naumann GO, Kruse FE, Cursiefen C: (2011) Prognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctiva. Ophthalmology. 2011;118(12): 2351-60
Scholz GA, Sirbu H, Semrau S, Anders K, Mackensen A, Spriewald BM: (2011) Persisting right-sided chylothorax in a patient with chronic lymphocytic leukemia: a case report. J Med Case Reports. 2011;5(): 492
Hönger G, Hopfer H, Arnold ML, Spriewald BM, Schaub S, Amico P: (2011) Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation. 2011;92(1): 41-7
Müller A, Zimmermann R, Krause SW: (2011) [Hemolytic anemias in adults]. Dtsch Med Wochenschr. 2011;136(45): 2308-12
Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A: (2011) Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial o J Clin Oncol. 2011;29(32): 4234-42
Baerenwaldt A, Lux A, Danzer H, Spriewald BM, Ullrich E, Heidkamp G, Dudziak D, Nimmerjahn F: (2011) Fc? receptor IIB (Fc?RIIB) maintains humoral tolerance in the human immune system in vivo. Proc Natl Acad Sci U S A. 2011;108(46): 18772-7
Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G, Prévost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Chaput N, Zitvogel L: (2011) IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 2011;71(16): 5393-9
Neumann M, Blau IW, Burmeister T, Tietze-Buerger C, Blau O, Gerbitz A, Uharek L, Thiel E: (2011) Intrathecal application of donor lymphocytes in leukemic meningeosis after allogeneic stem cell transplantation. Ann Hematol. 2011;90(8): 911-6
Ramsperger-Gleixner M, Spriewald BM, Tandler R, Kondruweit M, Amann K, Weyand M, Ensminger SM: (2011) Increased transcript levels of TNF-alpha, TGF-beta, and granzyme B in endomyocardial biopsies correlate with allograft rejection. Exp Clin Transplant. 2011;9(6): 387-92
Kelsch R, Everding AS, Kuwertz-Bröking E, Brand E, Spriewald BM, Sibrowski W, Konrad M, Dragun D: (2011) Accelerated kidney transplant rejection and hypertensive encephalopathy in a pediatric patient associated with antibodies against angiotensin type 1 receptor and HLA class II. Transplantation. 2011;92(10): e57-9
Hauschild A, Kolbl O, Mackensen A, Schadendorf D: (2011) [Forward]. Onkologie. 2011;34 Suppl 2(): 1
DREAM Trial Investigators , Holman RR, Zinman B, Yusuf S, Sheridan PM, Anand SS, Bosch JJ, Conget I, Davies MJ, Pirags V, Dagenais GR, Pogue JM, Zimmet PZ, Gerstein HC: (2011) Incidence of diabetes following ramipril or rosiglitazone withdrawal. Diabetes Care. 2011;34(6): 1265-9

Schriftgröße anpassen

Publikationen 2011

Publikationen 2011

Notfall

Notfallinformationen UKER

Patienten & Besucher

Ärzte & Zuweiser

Forschung

Lehre